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plinary panel and systematic literature review (SLR)-
-derived recommendations were voted according to the
Delphi method. The level of agreement among rheuma-
tologists was assessed using an online survey.
Results: Eight general and seven vaccine-specific re -
commendations were formulated. Briefly, immuniza-
tion status should routinely be assessed in all SIRD pa-
tients. The National Vaccination Program should be fol-
lowed and some additional vaccines are recommend-
ed. To maximize the efficacy of vaccination, vaccines
should preferably be administered 4 weeks before start-
ing immunosuppression or, if possible when disease
activity is controlled. Non-live vaccines are safe in
SIRD, including immunosuppressed patients. The safe-
ty of live attenuated vaccines in immunosuppressed pa-
tients deserves further ascertainment, but might be con-
sidered in particular situations.
Discussion: The present recommendations combine
scientific evidence with the multidisciplinary expertise
of our taskforce panel and attained desirable agreement
among Portuguese rheumatologists. Vaccination re -
commendations need to be updated on a regular basis,
as more scientific data regarding vaccination efficacy
and safety, emergent infectious threats, new vaccines as
well as new immunomodulatory therapies become
available.
Keywords:Antirheumatic agents; Immunosuppressive
agents; Biological products; Rheumatic diseases; Vac-
cination; Recommendations 
IntroductIon
Patients with rheumatic diseases are at higher risk for
infections, which contributes to increased morbidity
and mortality1-10. Several factors have been associated
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AbstrAct
Background: Serious infections are a major cause of
morbidity and mortality in systemic inflammatory
rheumatic disease (SIRD) patients.  Although vaccina-
tion may prevent numerous infections, vaccination up-
take rates are low in this group of patients. 
Objectives: To develop evidence-based recommenda-
tions for vaccination in SIRD patients.
Methods: We searched MEDLINE (until 31 October
2014) and EMBASE (until 14 December 2014) databa -
ses, as well as the ACR and EULAR congress abstracts
(2011-2014). Patients with any systemic inflammato-
ry rheumatic disease were included and all vaccines
were considered. Any safety and efficacy outcomes
were admitted. Search results were submitted to title
and abstract selection, followed by detailed review of
suitable studies. Data were subsequently pooled accor -
ding to the type of vaccine and the SIRD considered.
Results were presented and discussed by a multidisci-
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with increased susceptibility to infections, including
disease activity and medication, in particular im-
munosuppressants1-10. Effective and safe vaccination is
essential for the prevention of a significant number of
these infections11,12. However, vaccination uptake rates
among rheumatic patients are remarkably low13-19.
Over the years, several scientific societies have deve -
loped practice guidelines and/or recommendations
aiming to provide guidance on the optimal use of
vacci nes and improve vaccination adherence among
patients with rheumatic diseases20-23. According to
these recommendations, non-live vaccines can be gi -
ven safely to patients treated with immunomodulators.
The major differences among guidelines concern the
safe use of live attenuated vaccines, due to the scarci-
ty of data.
We aimed to develop evidence-based recommen-
dations for the vaccination of adult patients with sys-
temic inflammatory rheumatic diseases (SIRD), with a
particular focus on safety and efficacy of vaccination in
immunosuppressed SIRD patients.
Methods
We performed a comprehensive systematic literature
review (SLR), addressing the safety and efficacy of vac-
cination in systemic inflammatory rheumatic diseases
(SIRD). We searched MEDLINE (until 31 October
2014) and EMBASE (until 14 December 2014) databa -
ses. Additionally, we searched the abstracts of the
American College of Rheumatology (ACR) and Euro-
pean League Against Rheumatism (EULAR) congres ses
(2011-2014) and performed a complementary hand
search. Patients (both adults and children) with any
SIRD were included and all vaccines were considered.
Any safety and efficacy outcomes were admitted. Stu -
dies that assessed the simultaneous administration of
two or more vaccines (except commercially available
combinations), reviews and single case reports were
excluded.
Title and abstract selection was performed by 8 in-
dependent reviewers. The selected studies were sub-
mitted to independent detailed review (view Figure 1).
Translation was requested when needed. Study and
patient characteristics, the use of glucocorticoids and
immunosuppressants (both synthetic and biologic),
type of vaccine, as well as safety and efficacy outcomes
were independently extracted into piloted forms. Data
were subsequently pooled according to the type of vac-
cine and the SIRD considered. The quality of indivi -
dual studies was appraised using an adapted checklist
of 13 items24 (Appendix 1). Risk of bias was assessed
using the Cochrane Collaboration Tool25. Subsequen -
tly, a descriptive analysis was performed. 
SLR results were presented and discussed at a na-
tional meeting (63 participants) by a multidisciplinary
panel that included rheumatologists, infectious disea -
se specialists, experts on immunization, health pro-
fessionals and patients’ representatives. The taskforce
formulated eight general recommendations and seven
vaccine-specific recommendations for adult patients
with SIRD. Preliminary statements were afterwards
submitted to the appraisal of the entire group and vo -
ted according to the Delphi method. A minimum con-
cordance rate of 80% was considered necessary for the
approval of each individual statement as a final re -
commendation. When below this level of agreement,
the content and phrasing of each statement were dis-
cussed until a suitable concordance rate was attained.
The agreement with the final set of recommendations
was assessed using an online survey (52 participants);
participants were asked to score their level of agree-
ment with each recommendation using a 10-point
quantitative scale (from 0-total disagreement to 10-to-
tal agreement).
results
We retrieved 14594 abstracts. After title and abstract
selection, followed by the detailed review of the most
relevant results, 123 papers were identified. We ini-
tially planned to issue recommendations for both
adults and children with SIRD, but at the time of this
study another working group was preparing recom-
mendations for the pediatric population; therefore, 28
pediatric studies were additionally excluded and a fi-
nal total of 95 articles concerning adults with SIRD
were reviewed (Figure 1).
We obtained 65 papers on influenza vaccination26-91,
20 on pneumococcal92-112, 4 on viral hepatitis113-117, 2
on varicella zoster vaccine118-120 and 4 papers on va -
rious other vaccines (including papillomavirus121, po-
liomyelitis122, diphtheria/tetanus/pertussis (DTP)123
and yellow fever124 vaccines). Studies focused on diffe -
rent SIRD, namely rheumatoid arthritis, systemic lupus
erythematosus, spondyloarthritis, psoriathic arthritis,
primary systemic vasculitis, systemic sclerosis,
polymyositis, Sjögren’s syndrome, antiphospholipid
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antibody syndrome and undifferentiated connective
tissue disease. Table I summarizes the distribution of
included studies according to the disease and vaccine
considered. 
recoMMendAtIons
Eight general principles and seven vaccine-specific re -
co mmendations were formulated, reaching a high level of
agreement among Portuguese rheumatologists (Table II).
GenerAl prIncIples
1. The initial assessment of all patients with sys-
temic inflammatory rheumatic diseases (SIRD)
should include immunization status and catch-up
vaccination schedule, according to the National Vac-
cination Program, if necessary. Level of evidence125
2a; Grade of recommendation C; Agreement (mean and
standard deviation (SD)): 9.4 (1.3).
Vaccination was proven to be safe and effective in
the prevention of many infectious diseases26-125. How-
ever, particular safety and efficacy issues must be ta -
ken into consideration when vaccinating SIRD patients,
especially those on immunosuppressants30,31,36,38,93-
-95,98,101,102,109. The taskforce considered that the vacci-
nation status of all SIRD patients must ideally be as-
sessed at the moment of diagnosis and always before
starting immunosuppressive therapy.
2. Vaccines should be administered ideally at
least 4 weeks before starting any immunosuppres-
sive therapy and, when possible, disease activity
should be controlled. Level of evidence 4; Grade of
recommendation C; Agreement (mean (SD)): 8.5(1.9).
Early disease was considered a sensible time for vac-
cination, especially if live vaccines are considered. In
general, vaccines are safe and effective, regardless of
disease activity. A few studies included patients with
active disease who were able to mount an adequate im-
mune response and there was no consistent evidence
that vaccines lead to an increased number of flares or
PubMedn=13810
Detailed reviewn=242(not in English, n=13) Detailed reviewn=12(not in English, n=0)
Includedn=110(not in English, n=1) Includedn=5(not in English, n=0) Includedn=1(not in English, n=0)
123 included papers
95 final included papers
Includedn=7(not in English, n=0)
Embasen=588 ACR abstracts (11-14)n=73EULAR abstracts(11-14)
n=111
Manualsearchingn=12(not in English, n=0)
Excluded:• Pediatric population (n=28)
Excluded:• Not related (n=6)• wrong intervention (n=1)
Excluded by title/abstract:• Not related (n=514)• wrong population (n=9057)• wrong intervention (n=3996)• Language not translatable (n=1)
Excluded:• Not related (n=101)• wrong intervention (n=23)• wrong population (n=2)• Article not available (n=1)
Excluded by title/abstract:• Duplicated (n=83)• Not related (n=143)• wrong population (n=98)• wrong intervention (n=225)• Isolated summary (n=27)
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FIGure 1. Search strategy for the systematic literature review
adverse effects47,51,52,70,71,74,96,99,100,104,107,121,125. An excep-
tion was lower immunogenicity of influenza vaccina-
tion in SLE patients, a trait frequently related with disea -
se activity49. On the other hand, immunosuppressive
therapies (conventional DMARDs, biologics and mo -
derate to high doses of steroids) reduce the immuno-
genicity of non-live vaccines27,29,38,49,51,64,69,94,95,101,106,109,124.
The use of immunosuppression was very consistently
associated with lower efficacy of influenza and pneu-
mococcal vaccines in RA, SpA and CTD27,29,38,49,51,64,69,94,
95,101,106,109. This can reflect both a direct effect of the
drugs and indirectly the effect of disease activity. There-
fore, vaccines should preferably be administered to sta-
ble patients. Nonetheless, if stability cannot be achieved,
it is safe to vaccinate and it should be done, as the risk
of infection is likely to be increased in active SIRD126,127.
3. Patients receiving Rituximab should ideally be
vaccinated at least 4 weeks before the biological
therapy is started. When this is not possible, vac-
cination should occur 6 months after the previous
infusion (mean (SD)). Level of evidence 2a, Grade of
recommendation B, Agreement: 8.8(1.4).
Rituximab is a chimeric IgG1CD20-specific mono-
clonal antibody that depletes peripheral blood B cells
with subsequent reduction in differentiated plasma
cells (responsible for immunoglobulin production). Pa-
tients receiving rituximab have an impaired response to
inactivated or bacterial vaccines due to a reduction in
protective antibodies64,70,100,88,89,128,129. This is particular-
ly evident with pneumococcal vaccines, either conju-
gated or polysaccharide, where treatment with rituxi -
mab is associated with significantly lower antibody res -
ponse89,93,130. In patients in whom vaccination is indi-
cated, immunization should take place at least 4 weeks
before drug administration. If a patient has already re-
ceived rituximab, responses may be blunted at least
until B cell recovery occurs, which takes between 6 to
9 months.  Sometimes the ideal timing for vaccination
cannot be accomplished, particularly in case of sea-
sonal influenza, but in these situations the clinical
bene fit of vaccination still exists46,88,89,130.
4. Post vaccination assessment of antibody titers
is not routinely recommended except for hepatitis
B. Level of evidence 5; Grade of recommendation D;
Agreement (mean (SD)): 8.8(1.6).
In immunosuppressed patients, the response to he -
pa titis B immunization (measurement of anti-HBs
titers) should be assessed 4 to 8 weeks after completion
of the 3-dose schedule. A titer of anti-HBs above 10
IU/L should be considered protective. Titers of anti-
bodies after measles, rubella, varicella, pertussis and
mumps are neither reasonably specific nor sensitive.
Pneumococcal, tetanus and influenza vaccines are ac-
ceptably effec tive in SIRD patients; therefore, we do not
recommend the assessment of their post-vaccination
titers in daily clinical practice.
5. Non-live vaccines can be safely administered
du ring treatment with synthetic or biologic
DMARDs. Level of evidence 1b, Grade of recommen-
dation A; Agreement (mean (SD)): 9.3(1.0).
The efficacy and safety of several non-live vaccines
Portuguese recommendations for the Vaccination of adults with sird
4
ÓRGÃO OFICIAL DA SOCIEDADE PORtUGUESA DE REUMAtOLOGIA
tAble I. dIstrIbutIon oF the Included studIes AccordInG to the dIseAses And vAccInes Assessed
Vaccine RA SLE SpA/PsA PSV SSc/PM Other
Influenza 25 23 8 10 9 7
Pneumococcus 9 9 3 – – 1
Viral hepatitis 2 1 – 1 – –
Varicella zoster 3 1 3 – – –
Papillomavirus – 1 – – – –
Polio (oral) – 1 – – – –
DTP/ Tetanus 1 1 – – – –
Yellow fever 1 – – – – –
Please note that there is some overlap in the numbers because some studies included different SIRDs (≥1 patient) simultaneously.
RA: Rheumatoid arthritis, SLE: systemic lupus erythematosus, SpA: spondyloarthritis, PsA: psoriathic arthritis, PSV: primary systemic
vasculitis, SSc: systemic sclerosis, PM: polymyositis, JSIRD: juvenile systemic inflammatory rheumatic diseases, MMR - measles/mumps/
/rubella, DTP - diphtheria/tetanus/pertussis. Other diseases include: Sjögren’s syndrome, antiphospholipid antibody syndrome,
/undifferentiated connective tissue. 
cordeiro i et al
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Recommendations evidence125 Grade mean(SD)
General
The initial assessment of all patients with systemic inflammatory rheumatic 2a C 9.4 (1.3)
diseases (SIRD) should include immunization status and catch-up vaccination 
schedule, according to the national vaccination program, if necessary.
Vaccines should be administered ideally at least 4 weeks before starting any 4 C 8.5 (1.9)
immunosuppressive therapy and, when possible, disease activity should be 
controlled.
Patients receiving Rituximab should ideally be vaccinated at least 4 weeks before 2a B 8.8 (1.4)
the biological therapy is started. When this is not possible, vaccination should 
occur 6 months after the previous infusion.
Post vaccination assessment of antibody titers is not routinely recommended 5 D 8.8 (1.6)
except for hepatitis B.
Non-live vaccines can be safely administered during treatment with synthetic 1b A 9.3 (1.0)
or biologic DMARDs.
Live attenuated vaccines may be considered for certain patients receiving 4 D 7.9 (1.6)
immunosuppressive therapy.
Vaccination of close contacts should be strongly considered in certain situations, 5 D 8.1 (2.0)
depending on patient characteristics, degree of immunosuppression and the 
infectious agent.
Patients with SIRD who wish to travel should attend a travel medicine 2b C 9.0 (1.6)
consultation at least 6 months in advance.
Specific
Yearly anti-influenza vaccination is recommended to all patients with SIRD 2c B 8.7 (1.5)
regardless of current therapy.
Pneumococcal vaccination (PCV13 + PPSV23) is recommended for patients with 2b B 9.0 (1.5)
iatrogenic immunosuppression, including systemic corticosteroids and synthetic 
or biologic DMARDs (*).
The dosing schedule must take in consideration the patient's age and previous 2b B
immunization.
All SIRD patients with negative serology for hepatitis B virus (HBsAg, AntiHBc, 2b C 8.7 (1.4)
and AntiHBs negative) should be vaccinated.
In the case of isolated AntiHBc antibody positivity and negative viral load, 5 D
vaccination should be considered.
The response to vaccination should be assessed 1-2 months after the third dose, 2b C
and revaccination considered (0, 1 and 6 months) if seroprotection is not achieved.
Hepatitis A vaccination is recommended for SIRD patients travelling to endemic 2b B 8.9 (1.4)
areas, preferably with 2 doses 6 months apart.
Consider HPV vaccine with 3-dose series (0, 2 and 6 months) for young adults 2b C 8.6 (1.7)
with SIRD if not vaccinated previously.
Patients with SIRD should follow the recommended vaccination schedule in the 2b C 9.6 (1.0)
national vaccine program for anti-tetanic, i.e., every 10 years.
The individual assessment of the risk/benefit ratio of HZV is recommended 4 D 8.7 (1.7)
for patients with SIRD who are 60 years of age and older.
(*) Systemic corticotherapy ≥20mg/day Prednisolone or equivalent for ≥14 days; Methotrexate > 0,4 mg/Kg/week; Azathioprine > 3
mg/Kg/day; Leflunomide, Mycophenolate, Cyclophosphamide, Cyclosporine and Tacrolimus. Biological therapy or DMARDs used in
Rheumatoid Arthritis, Systemic Lupus Erythematous, Sjögren’s Syndrome and Inflammatory Bowel Disease, including anti-TNF (Infliximab,
Etanercept, Adalimumab, Golimumab, Certolizumab); Anti –CD20 (Rituximab); Anti-IL6 (Tocilizumab); CTLA-4-Ig (Abatacept); Anti-BLYS
(Belimumab); Anti-IL12 e Anti-IL23 (Ustekinumab); IL-1 antagonist (Anakinra/canakinumab).
in SIRD patients were assessed, namely influenza29,
pneumococcal66, hepatitis A116, hepatitis B115, human
papillomavirus vaccine121 and tetanus toxoid143. Most
studies assessed RA51,70 and SLE81,99 patients, with a less-
er extent of patients with systemic sclerosis, spondy-
loarthritis and primary systemic vasculitis29,52. The im-
munosuppressants considered included glucocorti-
coids87,101,110,121,128, various synthetic disease-modifying
antirheumatic drugs (sDMARD)69,101,110,121, cyclophos-
phamide29,45,99,100, tumour necrosis factor (TNF) block-
ing agents27,36,40,42,81-74,105, rituximab30,39,69,88,89, tocilizu -
mab64,102,104, abatacept59,60,104 and belimumab91. Al-
though sufficiently powered studies are lacking, vacci-
nation was globally safe. Most vaccine-related adverse
events reported were mild local and systemic adverse
events, apparently unrelated to either disease or im-
munosuppression. Serious adverse events were rare94,130
and were associated neither to vaccination nor to im-
munosuppression44.
The vast majority of studies support the idea that
vaccination with non-live vaccines is not significantly
associated with clinical or laboratorial flares comparing
to healthy controls70,81.
Thus, the taskforce considers that vaccination with
non-live vaccines can be safely administered during
immunosuppressant treatment, including sDMARD,
cyclophosphamide, TNF blockers, rituximab,
tocilizumab, abatacept and belimumab. 
6. Live attenuated vaccines may be considered
for certain patients receiving immunosuppressive
the rapy.
Level of evidence 4, Grade of recommendation D,
Agreement (mean (SD)): 7.9(1.6).
Live vaccines are prepared from live microorganisms
or viruses cultured under adverse conditions, leading
to loss of their virulence but maintenance of their abi -
lity to induce protective and long lasting immunity. The
administration of live vaccines bears the potential risk
of invasive infection in immunosuppressed patients.
The risk of infection is higher in live vaccines with a
high potential of replication (e.g. yellow fever vaccine)
rather than in vaccines with a low risk of replication (ty-
phoid oral vaccine, varicella/herpes zoster vaccine). In
most international guidelines, live vaccines are con-
traindicated during treatment with immunosuppres-
sants22,130-135. Although sufficiently powered studies are
lacking, there is growing evidence that live attenuated
viral vaccines, such as live-attenuated influenza136,137,
varicella–zoster virus119,120, MMR140,11,143 and yellow
Portuguese recommendations for the Vaccination of adults with sird
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fever virus125 vaccines might actually be safe for im-
munosuppressed patients in well-defined situations.
Our taskforce considered that live attenuated vac-
cines may be used with caution in SIRD patients. If a
live vaccine is indicated in a patient on immunosup-
pressive treatment, an individual assessment of the
risk/benefit must be performed, which includes di sease
activity, medication, the replication potential of the
vacci ne and the risk of infection. The risk assessment
by an infectious diseases or vaccination expert is en-
couraged. 
7. Vaccination of close contacts should be strong-
ly considered in certain situations, depending on
patient characteristics, degree of immunosuppres-
sion and the infectious agent. Level of evidence 4,
Grade of recommendation D, Agreement (mean (SD)):
8.1(2.0).
The aim of immunizing close contacts of SIRD pa-
tients is to counter the suboptimal immune respon-
siveness of immunosuppressed patients and to prevent
the transmission of vaccine-preventable pathogens to
these susceptible individuals138. Close contacts of im-
munosuppressed* patients, as well as health profes-
sionals participating in the care of immunocompro-
mised139 individuals*, should be offered routine annu-
al immunizations with inactivated influenza vaccine in
order to minimize disease spread140. Close contacts
should also comply or catch-up with the recommen ded
schedules for tetanus vaccination, pneumococcal,
MMR and varicella zoster virus (VZV) vaccines141,142.
Limited data are available on the risk of immunosup-
pressed individuals acquiring infection from a family
member or close contact who receives a live vaccine141.
Recent recommendations on primary immunodefi-
ciency note that microorganism transmission from
fami ly contacts receiving vaccines is a rare but possible
event141. Oral live polio vaccine is contraindicated in
immunocompromised patients143,144 and their house-
hold contacts141. An immunocompromised individual
without previous exposure to varicella zoster virus is at
minimal risk of transmission from a close-contact re-
cently immunized for VZV, unless blisters develop at
the site of administration. In this case, isolation of the
patient is recommended and varicella zoster im-
munoglobulin could be given prophylactically141.
(*) Systemic corticotherapy ≥20mg/day Pre dnisolone or
equivalent for ≥14 days; Methotrexate > 0,4 mg/Kg/week;
Azathioprine > 3 mg/Kg/day; Leflunomide, Mycophenolate,
Cyclophosphamide, Cyclosporine and tacrolimus. Biological
therapy or DMARDs used in Rheumatoid Arthritis, Systemic Lupus
Erythematous, Sjögren’s Syndrome and Inflammatory Bowel
Disease, including anti-tNF (Infliximab, Etanercept, Adalimumab,
Golimumab, Certolizumab); Anti –CD20 (Rituximab); Anti-IL6
(tocilizumab); CtLA-4-Ig (Abatacept); Anti-BLYS (Belimumab); 
Anti--IL12 e Anti-IL23 (Ustekinumab); IL-1 antagonist
(Anakinra/canakinumab).
8. Patients with SIRD who wish to travel should
atten d a travel medicine consultation at least 6
months in advance. Level of evidence 2; Grade of
recom mendation C; Agreement (mean (SD)): 9.0(1.6).
Immunocompromised individuals are at greater risk
of contracting disease while travelling than healthy per-
sons, particularly in destinations where several vaccine-
preventable infections are endemic. Anticipated plan-
ning is crucial to safe and successful travelling. A pre-
travel consultation with a travellers’ health, infectious
diseases, tropical medicine or vaccination expert is en-
couraged, so as to assess the risk of exposure to infec-
tions and other hazards during travel and to implement
adequate preventive strategies. The consultation must
be performed timely because patients may require des-
tination, transportation or accommodation adjust-
ments, catch-up and/or additional vaccination and also
disease chemoprophylaxis132. The taskforce considered
appropriate a minimum advance of 6-months to allow
time for completion of most multiple-dose vaccination
schemes. Inactivated vaccines can be safely adminis-
tered to patients on immunosuppression (view Gene -
ral Recommendation 5). These vaccines include those
against viral hepatitis A and B, Japanese encephalitis,
tick borne encephalitis and rabies, as well as the inacti -
vated form of the typhoid and polio vaccines (view Spe-
cific Recommendations). Specific vaccination and
chemoprophylactic strategies, including the adminis-
tration of live attenuated vaccines in this context,
should be based on an individual risk-benefit assess-
ment (view General Recommendation 6). 
b. vAccIne-specIFIc recoMMendAtIons
1. Influenza
Yearly anti-influenza vaccination is recommen -
ded to all patients with SIRD regardless of current
therapy. Level of evidence: 2c, Grade of recommenda-
tion: B; Agreement (mean (SD)): 8.7(1.5).
EFFICACY
Acute lower respiratory infections are a significant
concern in SIRD patients145-147. Multiple cohort studies
assessed the vaccine immunogenicity in different SIRD,
comparing the efficacy of the vaccine in patients under
different therapies or versus healthy controls. Most
studies indicate preserved immunogenicity to the in-
fluenza vaccine in SIRD*.
Rheumatoid arthritis. Influenza vaccination in RA pa-
tients was proven globally effective and leads to a re-
duction in respiratory infections37. It was suggested that
male gender, old age and smoking were related to worse
vaccine responses37,95,64. Treatment with methotrexate
(MTX), leflunomide and TNF inhibitors  was also as-
sociated with lower efficacy, but reasonable values of
seroprotection (SP) were obtained in the majority of
studies (SP>60-70%)26,36,38,40,47,51,70,73-75. Impairment of
the vaccine immunogenicity was more significant in
patients on rituximab and abatacept (seroconversion
(SC) 10-40%)36,46,59,64,65,85. Data on tocilizumab (TCZ)
are scarce, but one study showed that patients under
TCZ monotherapy have a better response to the vaccine
in comparison with patients treated with the associa-
tion TCZ+MTX54.
Spondyloarthritis (SpA). In general, H1N1 vaccina-
tion induced a protective response in SpA patients
(SP>60-70%). One sole study used the seasonal in-
fluenza vaccine, also with reasonable efficacy. There
was a tendency for better responses in SpA patients
when compared with RA patients. Within SpA patients,
better responses were observed in Ankylosing
Spondylitis (AS) versus Psoriatic Arthritis (PsA). Most
studies suggest that TNF inhibitors reduce the vaccine
responses. Older age (>60 years-old), smoking and
methotrexate treatment were also associated with low-
er efficacy27,29,52,55,64,73,74,95.
Connective tissue diseases (CTD) and primary systemic
vasculitis (PSV). Influenza vaccination was less effective
in SLE patients than in healthy controls. Nonetheless,
in a majority of studies, seroprotection rate was close
to 70%49,52,69,71,72. Steroid use (prednisolone in doses
above 10-20mg) and treatment with other immuno-
suppressants (azathioprine, mycophenolate, etc.) were
associated with lower efficacy69,71,80,91. Hydroxychloro-
quine might restore the immunogenicity in patients on
immunosuppressants71. In a sub-analysis of the BLISS
trial, patients on belimumab maintained the seropro-
tection over time likewise patients on placebo91. Fur-
thermore, newly vaccinated patients during the trial
had good vaccine responses independently of the treat-
ment group. In a heterogeneous group of 16 CTD pa-
tients treated with rituximab, the seroprotection was
not achieved in about half of cases39. Data concerning
other CTDs, including PSV are considerably limited.
However, data point to a similar efficacy to that ob-
served in SLE patients45,52,64.
cordeiro i et al
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SAFETY
Safety outcomes included all adverse events (in-
cluding local and systemic effects), disease activity
scores and autoantibody measurements in a variable
time period after the vaccine administration.
RA.The influenza vaccine exhibited an excellent safe-
ty profile, in spite of past or present therapy. No serious
adverse events were reported. Mild local reactions and
flu-like symptoms were described in slightly higher fre-
quencies of those observed in healthy population. Five
studies reported elevation of disease activity after vac-
cine administration, but this result was contra dicted in
twelve other studies22,26,28,29,46,47,50-52,54,59,60,64,65,70,72-75,77.
SpA. Safety issues were poorly described, as no stu -
dies specified the occurrence of adverse events. Vacci-
nation does not seem to influence disease activi-
ty27,29,36,52,55,64,73,74.
CTD and PSV. Vaccination in SLE patients is general -
ly safe. Mild adverse events (local reaction and flu-like
syndromes) occurred with variable frequency (5-41%).
In all 17 studies which addressed safety issues, two se-
rious events were reported (an acute myocardial in-
farction and a deep venous thrombosis), that were not
considered to have a causal relationship with the vac-
cine. Some studies report a transitory rise in auto-an-
tibody titers40,43,44,49,61,63,69,71,78-80,87,90,91.Vaccination does
not seem to influence disease activity27,29,36,52,55,64,73,74.
There are conflicting results on the frequency of
flares after vaccination, though eight out of twelve stu -
dies did not show an increased frequency of flares. 
(*) European Guidelines propose that an efficacious influenza
vaccine should confer a seroprotection (SP) rate >70% or a
seroconversion (SC) rate >40% in adults between 18 and 60
years-old148.
2. pneuMococcAl
a) 23-valent Pneumococcal polysaccharide vac-
cine (VPP23) and 13-valent Pneumococcal conjugate
vaccine (VPC13) are recommended in patients with
iatrogenic immunosuppression, including systemic
corticosteroids and synthetic or biological Disease-
-Modifying Antirheumatic Drugs (DMARDs)* Level
of evidence 2b, Grade of recommendation B.
b) Schedule for pneumococcal vaccination must
take into consideration patients age and previous
immunization status. Level of evidence 2b, Grade of
recommendation B.
Agreement (all statements, mean (SD)): 9.0(1.5).
INDICATIONS
Streptococcus pneumoniae infection is responsible for
substantial mortality and morbidity in elderly adults
(aged ≥ 65 years) or with underlying chronic or im-
munosuppressive conditions149-151. Vaccination plays a
crucial role in protection from infections caused by these
bacteria151. At the moment, 2 pneumococcal vaccines
are available: 23-valent polysaccharide vaccine (VPP23)
and 13-valent conjugate vaccine (VPC13). VPP23 in-
duces antibodies primarily by T-cell-independent mech-
anisms, therefore without development of immunolog-
ical memory152. The levels of antibodies directed to most
pneumococcal vaccine antigens remain elevated for at
least 5 years and decrease progressively to prevaccina-
tion levels within 10 years. A more rapid decline may
occur in immunosuppressed patients and in elderly per-
sons151-154. For this reason, patients on immunosup-
pressants should be revaccinated with VPP23 a second
time within 5 years from the first dose. However, more
than one re-vaccination is not recommended since vac-
cination with pneumococcal polysaccharide antigens
may induce hyporesponsiveness and a less robust anti-
body response may occur on the subsequent doses153.
VPC13 has a conjugated protein in its formulation that
is recognized by T-cells, stimulating serum antibody re-
sponse and immunologic memory. Therefore, revacci-
nation with VPC13 is not indicated. VPC13 also boosts
the immunological res ponse to VPP23, stimulates mu-
cosal immunity and decreases nasal and oropharynx
colonization155.
Patients should be vaccinated according to the fol-
lowing schedule (Figure 2)139,155,156:
In patients who have not been previously vacci-
nated, a single dose of VPC13 should be given, fol-
lowed by a dose of VPP23 at least 8 weeks later. Pa-
tients should be revaccinated with VPP23 at least 5
years from the first dose (this second those can be gi -
ven either before 65 years old or after).
For individuals who have already been vaccina ted
with VPP23, a single dose of VPC13 should be gi ven
1 or more years after the last dose of VPP23. Revacci-
nation with VPP23 should occur 5 years after the last
dose and no sooner than 8 weeks after VPC13. 
EFFICACY
In general, pneumococcal vaccination turned out to
be as effective in patients with SIRD as in healthy con-
trols. Regarding SLE patients, there are conflicting re-
sults, with two studies demonstrating lower efficacy92,97
and a shorter seroprotection period (42% of SLE pa-
tients lost SP 3 years after immunizations97). However,
treatment with methotrexate, TNF inhibitors and ri -
tuximab is associated with lower efficacy either with
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VPP23 or VPC13, as it was demonstrated in three 
studies involving patients with SpA (including
PsA)94,106,110  and in seven studies in patients with
RA93,95,101,103,104,108,112. Data on tocilizumab (TCZ) and
abatacept (ABA) are scarce, with only two studies
demonstrating no ne gative impact in seroprotection in
RA patients receiving TCZ101,104 and one study showing
that ABA reduces the efficacy of VPC13 in RA pa-
tients104. With regard to belimumab, there is only one
study available in patients with SLE, showing no im-
munological impairment after pneumococcal vaccina-
tion in patients receiving belimumab91.
SAFETY
Several studies demonstrate that pneumococcal im-
munization is safe, with only one study in RA and SpA
patients treated with anti-TNF reporting two serious
adverse events (pneumonia and soft tissue infection)94.
Both vaccines appear not to influence disease activi-
ty96,99,104,107,108.
(*) Systemic corticotherapy ≥20mg/day Predni so lone or
equivalent for ≥14 days; Methotrexate > 0,4 mg/Kg/week;
Azathioprine > 3 mg/Kg/day; Leflunomide, Mycophenolate,
Cyclophosphamide, Cyclos porine and tacrolimus. Biological
therapy or DMARDs used in Rheumatoid Arthritis, Systemic Lupus
Erythematous, Sjögren’s Syndrome and Inflammatory Bowel
Disease, including anti-tNF (Infliximab, Etanercept, Adalimumab,
Golimumab, Certolizumab); Anti –CD20 (Rituximab); Anti-IL6
(tocilizumab); CtLA-4-Ig (Abatacept); Anti-BLYS (Belimumab); Anti-
IL12 e Anti-IL23 (Ustekinumab); IL-1 antagonist (Anakinra/
/canakinumab).
3. hepAtItIs b
a) All SIRD patients with negative serology for
hepatitis B virus (HBsAg, AntiHBc, and AntiHBs
negative) should be vaccinated. Level of evidence 2b;
Grade of recommendation C.
b) In the case of isolated antiHBc antibody posi-
tivity and negative viral load, vaccination should be
considered. Level of evidence 5; Grade of recommen-
dation D.
c) The response to vaccination should be as-
sessed 1-2 months after the third dose, and revac-
cination considered (0, 1 and 6 months) if seropro-
tection is not achieved. Level of evidence 2b; Grade
of recommendation C. Agreement (all statements,
mean (SD)): 8.7(1.4).
INDICATIONS
Universal hepatitis B (HB) vaccination is recom-
mended for all Portuguese children and adults, ac-
cording to the National Vaccination Program (PNV)159.
This has resulted in a great decrease in HB incidence
over the past two decades160. SIRD patients have an in-
creased risk of liver disease due to drug toxicity (syn-
thetic and biologic DMARDs, NSAIDs) and infectious
diseases (including acute/chronic HB and reactivation
of past HB due to severe immunosuppression). 
USE
In order to prevent the development of a potential
comorbidity that could seriously interfere with the
treatment and outcome of SIRD patients, HB vaccina-
tion (3 doses: 0, 1 and 6 months) is recommended for
all patients with negative serology (HBsAg, AntiHBc,
and AntiHBs negative). One to two months after the
third dose of the vaccine (i.e. 7-8 months after starting
the vaccination scheme), AntiHBs titers should be mea-
Without previousvacination
Previous vaccinationwith VPP23
















FIGure 2. Pneumococcal vaccination schedule
Adapted from Froes F, Diniz A, Robalo Cordeiro C, Serrado M, Ramalho de Almeira A. Consensus document for the prevention of
respiratory infections in adults. Sociedade Portuguesa de Pneumonologia. Rev Port de Pneumonologia. 2014;20(2):111-1114
sured so as to assess response to vaccination114,115,117.
Seroprotection is defined as a serum titer above 10IU/L
and, if it is not achieved, revaccination should be con-
sidered. Only one study addressed this question in two
inactive SLE patients, not on DMARDs, that respon ded
to vaccination only after a 4th dose114. However, based
on expert recommendations, a repetition of the com-
plete 3-dose scheme – 0, 1 and 6 months – should be
preferred if patients fail to respond at first.
There is no available evidence concerning the effect
of accelerated (0-1-2-12 months) or superaccelerated
schedules (0-7-21-360 days) of HB vaccination on
SIRD patients and, therefore, no recommendations can
be issued for these strategies. However, this might be
an option if a rapid immune response is needed.
EFFICACY
Despite the limited number of studies available, HB
vaccination of SIRD patients was effective in 68-93% of
cases114,115,117. Importantly, lower responses were re-
ported in the study where most RA patients were treat-
ed with MTX, other sDMARDs and/or glucocorti-
coids115. There were no data available on the effect of
biologics on vaccine efficacy.
SAFETY
There were no reports of safety or disease-wor sening
issues. Based on these data, on extrapolation from 
other vaccines and experts’ opinion, HB vaccine can and
should be administered in every SIRD patient without
protective antibodies for HBV. Patients who present iso-
lated positive AntiHBc due to previous contact with
HBV may still benefit from vaccination, in order to gene -
rate AntiHBs antibodies that can be protective in the
event of reexposure. Confirmation of undetectable vi-
ral load should be attained prior to immunization. 
4. hepAtItIs A 
a) Vaccination is recommended for SIRD patients
travelling to endemic countries, preferably with 2
doses 6 months apart. Level of evidence 2b; Grade of
recommendation B; Agreement: 8.9(1.4).
INDICATIONS
The incidence of hepatitis A (HA) has dramatically
decreased in Portugal in the last 20 years due to major
improvements in the overall environmental and so-
cioeconomic conditions160-162. Universal HA vaccina-
tion is, thus, currently not recommended and is limit-
ed to individuals travelling to high prevalence coun-
tries (Africa, South and Central America, parts of Asia
and Eastern Europe) or during an outbreak of dis-
ease163,164. In some patients with liver disease or at high
risk for hepatotoxicity, due to the occurrence of occa-
sional outbreaks of hepatitis A related to contamina-
tion of imported foods with hepatitis A virus, immu-
nization should be considered even if travel is not ex-
pected163,164. Due to the decrease in the prevalence of
HA in Portugal, the number of susceptible younger in-
dividuals has risen and this could lead to greater and
more frequent outbreaks164. Protecting more vulnera-
ble patients through immunization would prevent po-
tentially serious liver disease or worsening of the SIRD
due to suspension of hepatotoxic DMARDs.
USE
For SIRD patients, two doses of the vaccine should
be administered (0 and 6 months) before travelling, in
order to ensure adequate protection116.
EFFICACY AND SAFETY
In a cohort study of 53 RA patients treated with TNF
blockers ± MTX, vaccination response was low after
the first dose (6-20%), especially in patients exposed to
MTX, and greatly increased after the second (82%)116.
No adverse events were reported116.
5. pApIlloMAvIrus
a) Consider HPV vaccine with 3 doses scheme
(0, 2 and 6 months) in young adults with SIRD that
have not been previously vaccinated. Level of evi-
dence: 2b, Grade of recommendation: C, Agreement
(mean (SD)): 8.6(1.7).
INDICATIONS
Quadrivalent human papillomavirus (HPV) vaccine
is a recombinant vaccine against HPV serotypes 6, 11,
16 and 18. It is included in the Portuguese National
Vaccination Plan and scheduled as a 2-dose series (0
and 2 months) for all girls between 10 to 13 years old;
a 3-dose series (0, 2 and 6 months) is used for women
between 18 and 25 years old165. Systemic Lupus Ery-
thematosus (SLE) patients have an increased incidence
of human papillomavirus (HPV) infection and cervical
dysplasia. HPV clearance is also decreased comparing
to the general population166,167. Experts suggest that
HPV vaccination should also be extended to males in
order to achieve universal immunity.
USE
In the opinion of our taskforce, young adult SIRD
patients (both male and female) should be considered
for HPV vaccination if not previously immunized.
EFFICACY AND SAFETY
HPV vaccine is safe and effective in SLE patients with
stable disease121. No evidence is available for other
SIRD, but as with other non-live vaccines, HPV vac-
Portuguese recommendations for the Vaccination of adults with sird
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cine is considered safe in immunosuppressed patients
(General Recommendation 5). 
6. tetAnus
a) Patients with SIRD should follow the recom-
mended vaccination schedule in the National Vac-
cine Program, i.e. tetanus and dyphteria (Td) every
10 years. Level of evidence 2b, Grade of recommen-
dation B, Agreement (mean (SD)): 9.6(1.0).
INDICATIONS
SIRD patients should follow the National Vaccina-
tion Program schedule169.
EFFICACY
Tetanus toxoid vaccination (TTV) immunogenicity
was shown to be reduced in RA and SLE patients com-
paring to healthy controls, independently of the use of
glucocorticoids and immunosuppressants124,128,168. The
efficacy of the vaccine when administered 2 weeks after
rituximab was similar to methotrexate monotherapy66.
Nevertheless, as immunogenicity might be decreased
within 1-3 months after B-cell depleting the rapy, it is rec-
ommended to vaccinate patients 4 weeks before initia-
tion of therapy, or alternatively 6-8 months after the last
infusion (General Recommendations 2 and 3).
SAFETY
TTV was demonstrated to be safe in RA and SLE pa-
tients124,128,168.
7. herpes Zoster
a) In patients with SIRD over 60 years it is 
re commended individual assessment of the risk/be -
ne fit of HZ vaccine. Level of evidence 4, Grade 
of re commendation D, Agreement (mean (SD)):
8.7(1.7).
INDICATIONS
Herpes zoster (HZ) has an incidence of 34/1000
people-year and will affect 1 in 3 adults. Following na -
tural infection (varicella or chickenpox) or vaccination,
varicella zoster viruses (VZV) reside, latent, on the dor-
sal root ganglia. Over time, reactivation may occur,
mainly by changes in cell mediated immunity. The vac-
cine reduced the risk for developing zoster by 51% and
prevented post-herpetic neuralgia (PHN) in 67% per-
sons. In general, with increasing age at vaccination de-
clines the vaccine efficacy, but the vaccine retained ef-
ficacy against severity of zoster better than against
zoster itself. For persons older than 80 years the effi-
cacy against zoster was 18%, but the efficacy against
PHN was 39%175.
Patients with SIRD have an increased risk for herpes
zoster170-174. Immunosuppressed patients have a high-
er risk of severe rash, visceral dissemination or death,
whereby prevention is desirable176-178. On the other
hand, the administration of live vaccines, such 
as HZ vaccine bears the potential risk of invasive in-
fection in susceptible individuals (General Recom-
mendation 6).
According to the Center of Disease Control and Pre-
vention Advisory Committee on Immunization Prac-
tices Recommendations (CDC-ACIP) and the American
College of Rheumatology (ACR), herpes zoster vacci-
nation should be considered in patients >60 years-old
who are receiving: prednisone <20 mg/day, short term
(<2 weeks) corticosteroids, topical or intraarticular cor-
ticosteroids, ‘low dose’ methotrexate (defined as <0.4
mg/kg/week), azathioprine (<3.0 mg/kg/day) or 6-mer-
captopurine (<1.5 mg/kg/day). The guidelines do not
address vaccine use when these agents are combined.
They state the vaccine should not be given in the fol-
lowing circumstances: treatment with biologics (speci -
fically naming adalimumab, infliximab and etaner-
cept); high dose corticosteroids > 20 mg/day for more
than two weeks; active leukemia, lymphoma, malig-
nant neoplasm affecting bone marrow or lymphatics;
AIDS/HIV patients and those with CD4 lymphocyte
counts < 200 per mm3 clinical or laboratory evidence
of cellular immunodeficiency (patients with hy-
pogammaglobulinemia or dysgammaglobulinemia can
receive the zoster vaccine); hematopoetic stem cell
transplantation; pregnancy and severe acute illness.
EFFICACY
In our SLR, we found two large retrospective stu dies
concerning VZV vaccination in SIRD patients, inclu -
ding patients receiving biologics119,120. VZV vaccine
(single dose of 0.65mL subcutaneously) was adminis-
tered to RA, PsA, SpA, psoriasis and inflammatory bow-
el disease patients treated with TNF inhibitors (n=553),
non-TNF biologics (n=82), DMARDs and/or glucocor-
ticoids (average dose 14.02 mg/day, range 2.5-
-50mg/day). Immunization was associated with a long-
-term (2 years of follow-up) protective effect119,120.
SAFETY
HZV was not associated with an increase of HZV in-
fections up to 42 days after vaccination (95%CI - 0-5.4
cases per 1000 anti-TNF users and 0-4.7 per 1000 bio -
logic users)119,120. The vaccine also appears to be safe
and well tolerated by SLE patients, but reduced effec-
tiveness is a concern118.
USE
In light of the available evidence, our taskforce con-
cordeiro i et al
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sidered that the risk/benefit of the HZV must be indi-
vidually assessed, including patient age, disease activi -
ty, medication and the risk of infection.
Table III summarizes information on review vac-
cines, such as type of vaccine, recommended use and
dosing schemes.
conclusIons
Thirteen evidence-based recommendations for vacci-
nation in adult patients with SIRD were elaborated ai -
ming to improve care for these patients.  
The present recommendations combine scientific
evidence with the expertise of a multidisciplinary pa -
nel and attaining desirable agreement among Por-
tuguese rheumatologists. For dissemination purposes,
the current paper will be published in a MEDLINE-in-
dexed journal and will be freely available online at the
SPR website. SPR members will be notified by email
and/or newsletter after publication. However, there are
still many areas deserving future research (Table IV).
Most studies used surrogate markers of efficacy, such as
seroprotection and seroconversion, instead of the oc-
Portuguese recommendations for the Vaccination of adults with sird
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tAble III. suMMArIZed InForMAtIon on vAccInes, recoMMended use And dosInG scheMes
Vaccine Type Use Dosing schemes
Non-live vaccines
Influenza Inactivated All SIRD patientsa Yearly administration
Pneumococcal - VPC13b Conjugate All SIRD patientsa Single dose (If previous PPSV23
vaccination, >1 year (y) interval 
is recommended)
Pneumococcal – PPSV23c Inactivated All SIRD patientsa First dose: ≥8 weeks after VPC13
Second dose: 5 y after 1st
Hepatitis B Subunit Negative serology for Hep B Dosing: 0, 1 and 6 monthsh (mo)
or Assess Ac. Anti-Hbs titer 1-2 mo 
Isolated antiHBc antibody after the last dose
positivity and negative viral load Revaccinate if titer <10 IU/L
Hepatitis A Inactivated Susceptible travellers to endemic 0 and 6 moh
regions
Papillomavirus Subunit Young adults (female or male) 0, 2 and 6 mo
not previously vaccinated
Tetanus/diphtheriad Toxoid All SIRD patientsa Every 10 y
Poliomyelitis (parenteral)d Inactivated Unvaccinated or incompletely Scheme: 0, 1 and 6-12 mo.
vaccinated patients Single booster ≥10y after scheme
completion
Live attenuated viral vaccines 
(LAVV)e
Varicella LAVV Susceptible persons (negative Dosing: 0 and 4 weeks
anti-VZV)
Varicella zoster (herpes zoster) LAVV SIRD patients ≥60 yo.i Single dose
MMRd,f LAVV Selected SIRD patientsd Single dose
Yellow feverg LAVV Travelers to endemic regions Single dose
a. Ideally ≥4 weeks before any immunosuppressive treatment or ≥6 months after rituximab, controlled disease activity is advised; b. VPC13: 
13-valent Pneumococcal conjugate vaccine; c. VPP23: 23-valent Pneumococcal polysaccharide vaccine; d. SIRD patients should comply with
the National Vaccination Program recommendations for adults ≥18 yo; e. The administration of live vaccines must be based in an individual
assessment of the risk/benefit, which includes disease activity, medication, the replication potential of the vaccine and the risk of infection; 
f. MMR: measles, mumps, rubella; g. Previous consultation with a Traveller’s Medicine Specialist is recommended; h. Accelerated 
(0-1-2-12 months) or superaccelerated schedules (0-7-21-360 days) of HB vaccinationcan be used for people travelling on short notice that
face imminent exposure or for emergency responders to disaster areas. A combined hepatitis A and hepatitis B vaccine can also be used on
the same 3-dose schedule (0, 7, and 21–30 days), with a booster at 12 months. However, these vaccination schemes have not been tested in
SIRD patients; i. Receiving prednisone <20 mg/day, short term (<2 weeks) corticosteroids, topical or intraarticular corticosteroids, ‘low dose’
methotrexate (defined as <0.4 mg/kg/week), azathioprine (<3.0 mg/kg/day) or 6-mercaptopurine (<1.5 mg/kg/day).
currence of infections as the primary study outcome.
Definite conclusions on the impact of disease activity
or immunosuppressive drugs on the safety of vaccina-
tion were limited by variability in the measures used in
the assessments. Evidence was also scarce on various
other contexts (Table IV).
The reader of these recommendations should 
keep in mind that many recommendations given in 
this article are based on clinical experience and expert
opinion as scientific data are still scarce on many as-
pects.
Vaccination recommendations need to be updated
on a regular basis, as more scientific data regarding
vacci nation efficacy and safety, emergent infectious
threats, new vaccines as well as new immunomodula-
tors become available.
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AppendIX I – QuAlIty AssessMent oF vAccInAtIon studIes
deFInItIon oF study populAtIon:
1. Sufficient description of characteristics of study groups 
A ‘1’ is given when a paper describes at least setting and time period of the study, ages of patients (and its
range), sex and ongoing medication
2. Definition of diagnosis:
Rheumatic disease diagnosis
diagnosis was according accepted classification criteria. 
3. Selection bias:
Clear description of selection of study subjects.
When a paper described how the study subjects were selected (description of in- and exclusion criteria) from
the population level to the study level, a ‘1’ will be given. 
4. Follow-up:
Follow-up time ≥ 6 weeks for rheumatic disease patients.
6 weeks was seen as an acceptable follow-up duration to assess antibody production 
5. Organization of follow-up 
A ‘1’ was given if there was a structured follow-up applied (efficacy and safety). So not only on patients
request. 
6. Participation rate ≥ 80% for study groups
80% was an arbitrary margin chosen to determine the quality of the selection of study subjects. 
7. No differences in lost to follow-up (in both groups) 
Including (quantitative and qualitative) information on completers and non-completers 
8. Assessment of the outcome: 
Valid measures of vaccine efficacy Reliable assays used for antibody titer measurement; 
Immunologic outcome assessment was blinded to clinical data (at least treatment and symptom
duration)
A ‘1’is given if the observers were blinded to the intervention 
9. Safety assessment was performed using valid measures 
For example A ‘1’is given if disease flare was according to accepted definitions
Analysis and Data Presentation
10. Frequencies of most important comorbidities were given
11. Immunosuppressant medication use and dosage was given
12. Frequencies of important outcomes studied were given 
13. Appropriate analysis techniques with estimates were used 
TOTAL QUALITY RATE (x/13)
Adapted from: Kwok WY, Plevier JW, Rosendaal FR, Huizinga TW, Kloppenburg M. Risk factors for progression in hand osteoarthritis: a sys-
tematic review. Arthritis Care Res (Hoboken). 2013;65:552-562. 
